Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 629pembrolizumab 559Magnetic Resonance Spectroscopy 539Carboplatin 423Cyclophosphamide 371Cisplatin 371Biopsy 357Paclitaxel 304Nivolumab 301Gemcitabine 299Radiotherapy 270Bevacizumab 238Dexamethasone 207fludarabine 205Docetaxel 189durvalumab 178atezolizumab 176Oxaliplatin 172Fluorouracil 167venetoclax 164Rituximab 164Pemetrexed 162Radiation 159Doxorubicin 159Capecitabine 158Radiosurgery 147Etoposide 137Ipilimumab 134Leucovorin 133Lenalidomide 130

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Serotonin 5-HT3 Receptor Antagonists × 90 days × Clear all
NCT06925737 2026-05-29

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,440 enrolled
Genitourinary

Prostatic Neoplasms

NCT06780085 2026-05-26

MK-3475-01H

Merck Sharp & Dohme LLC

Phase 2 Recruiting
96 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡